Neurocrine Biosciences develops and commercializes therapies for neurological, neuroendocrine, and psychiatric disorders, including its lead product Ingrezza for tardive dyskinesia.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Steve Cohen / Point72 | — | New buy | 2,019 | $283,485 | 0.0% |
| Bridgewater | 49 | Added +158% | 23,038 | $3,234,074 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.